期刊文献+

IL-4、IFN-γ在特发性肺纤维化患者血清中的检测及意义 被引量:4

Detection and significance of serum levels of IL-4 and IFN-γ in patients with idiopathic pulmonary fibrosis
下载PDF
导出
摘要 目的探讨血清白细胞介素(IL-4)、干扰素(IFN-γ)水平在特发性肺纤维化(IPF)发生发展中的意义。方法应用双抗体夹心酶联免疫吸附试验法(ELISA)方法对27例IPF患者治疗前与治疗3个月后有效组(n=18)和无效组(n=9)外周血血清中的IL-4、IFN-γ含量进行检测分析。结果 IPF患者血清中的IL-4水平高于健康对照组(P<0.05),血清IFN-γ水平低于健康对照组(P<0.05)。血清IL-4水平治疗后有效组较治疗前降低(P<0.05),无效组较治疗前升高(P<0.05),血清IFN-γ水平治疗后无效组比治疗前降低(P<0.05)。结论 IPF的病情进展与患者血清中IL-4水平增高或者IFN-γ的水平降低有关,检测血清中IL-4、IFN-γ含量变化特点有助于了解其与IPF的关系,可能进一步作为IPF辅助诊断的有效指标。 Objective To investigate the significance of the serum levels of interleukin - 4 ( IL - 4 ) and interferon - γ ( IFN - γ) in idio- pathic pulmonary fibrosis (IPF) pathogenesis. Methods Double -antibody Sandwich ELISA was applied to detect IL-4 and IFN -γ levels in peripheral blood serum of 27 IPF patients prior to and 3 months after treatment. Results Compared to the control group, IL -4 level in IPF patients was higher ( P 〈 0. 05 ) , while IFN - γ level was lower ( P 〈 0. 05 ). IL - 4 level was decreased in patients after effective treatments ( P 〈 0.05 ). and increased in those with noneffective treatments ( P 〈 0.05 ). However, IFN - γ level was decreased in patients after noneffective treatments ( P 〈 0. 05 ). Conclusion The high level of IL - 4 or the low level of IFN - γ may relate with IPF pathogenesis. The changes of the levels of IL - 4 and IFN - γ can be served as auxiliary diagnostic markers of IPF.
出处 《临床和实验医学杂志》 2013年第1期24-25,27,共3页 Journal of Clinical and Experimental Medicine
关键词 特发性肺间质纤维化 白介素-4 Γ干扰素 Idiopathic pulmonary fibrosis Interleukin - 4 Interferon - γ
  • 相关文献

参考文献9

  • 1Green FH. Overview of pulmonary fibrosis[J].Chest,2002,(06):334S-339S.
  • 2Raghu G,Collard HR,Egan JJ. An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management[J].American Journal of Respiratory and Critical Care Medicine,2011,(06):788-824.
  • 3侯杰.现代肺弥漫性疾病学[M]北京:人民军医出版社,2003249.
  • 4Keel M,Trentz O. Pathophysiology of polytrauma[J].Injury.British Journal of Accident Surgery,2005,(06):691-709.
  • 5牟晓燕,林殿杰,辛洪涛.肺间质纤维化的分子生物学发病机制及治疗新进展[J].国际呼吸杂志,2006,26(12):928-931. 被引量:17
  • 6Sharma R,Guleria R,Pande JN. Idiopathic pulmonary fibrosis:newer concepts and management strategies[J].Indian Journal of Chest Diseases and Allied Sciences,2003,(01):31-49.
  • 7Billiau A,Matthys P. Interferon-gamma:a historical perspective[J].Cytokine & Growth Factor Reviews,2009,(02):97-113.
  • 8Klingsberg RC,Mutsaers SE,Lasky JA. Current clinical trials for the treatment of idiopathic pulmonary fibrosis[J].Respirology,2010,(01):19-31.
  • 9Strieter RM,Starko KM,Enelow RI. Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis[J].American Journal of Respiratory and Critical Care Medicine,2004,(02):133-140.

二级参考文献20

  • 1Gurujeyalakshmi G,Hollinger MA,Giri SN,et al.Regulation of transforming growth factorβ1 mRNA expression by taurin andniacin in the bleomycin Hamster model of lung fibrosis.Am J Repir Cell Mol Biol,1998,18(3):334-336.
  • 2Kosowsk R,Knoch KP,Wenzel KW,et al.Proteinases and proteinase inhibitors during the development of pulmonary fibrosis inrat.Clin Chim Acta,1998,271 (1):45-47.
  • 3Yao HW,Xie QM,Chen JQ,et al.TGF-beta1 induces alveolar epithelial to mesenchymal transition in vitro.Life Sci,2004,76(1):29-37.
  • 4Douglas W,Ryu J H,wensen SJ,et al.Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis:a randomized prospective study.A m J Respi r Crit Care Med,1998,158(1):220-226.
  • 5Molteni A,Moulder JE,cohen EF,et al.Control of radiationinduced pneumopathy and lung fibrosis by angiotensinconverting enzyme inhibitors and an angiotensin Ⅱ type Ⅰ receptor blocker Int.J Radiat Biol,2000,76 (4):523-532.
  • 6Li Y,Azuma A,Usuki J,et al.EM703 improves bleomycin induced pulmonary fibrosis in mice by the inhibition of TGFbeta signaling in lung fibrosis.Respir Res,2006,7 (1):16-20.
  • 7Behr J,Maier K,Degenkolb B,et al.Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis:adjunctive therapy to maintenance immunosuppression.Am J Respir Crit Care Med,1997,156(6):1897-1901.
  • 8Raghu G,Johnson WC,Lockhart D,et al.Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent,pirfenidone:results of a prospective,openabel Phase Ⅱ study.Am J Respir Crit,Care Med,1999,159(4 pt 1):1061-1064.
  • 9Azuma A,Expectation of new treatments for idiopathic interstitial pneumonias.Nippon Ronen Igakkai Zasshi,2005,42(1):27-30.
  • 10Ziesche R,Hofbauer E,Wittmann K,et al.A preliminary study of long term treatment with interferon Gamma-1b and low dose prednisolone in patients with idiopathic pulmonary fibrosis.Am J Respir Cell Mol Biol,2004,31(6):679-686.

共引文献16

同被引文献71

引证文献4

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部